Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST).

YEN-WEN WUWei, Chao-HungChao-HungWeiYEN-HUNG LINSHANG-YI HUANGLiu, Yen-WenYen-WenLiuTan, Tran-DerTran-DerTanYu, Wen-ChungWen-ChungYuLiu, Chia-JenChia-JenLiuHung, Chung-LiehChung-LiehHungKo, Po-ShenPo-ShenKoYang, Ning-INing-IYangCho, Shih-FengShih-FengChoHuang, Chun-YaoChun-YaoHuangLiao, Chun-KaiChun-KaiLiaoJerry Teng, Chieh-LinChieh-LinJerry TengChen, Tsai-YunTsai-YunChenWEN-JONE CHENBOR-SHENG KO2025-06-042025-06-042025-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/729901Light chain (AL) amyloidosis, defined by the organ deposition of misfolded and aggregated amyloid light chain, is the most common subtype of systematic amyloidosis with an incidence rate of around 1 case per 100,000 person-years in Taiwan. Due to its rarity, and heterogeneous initial presentation depending on the affected organs, diagnosis and management of AL amyloidosis are challenging. To increase the awareness of AL amyloidosis across clinical specialties and provide evidence-based recommendations, the Taiwan Society of Cardiology (TSOC) and Hematology Society of Taiwan (HST) have jointly developed a position statement. The joint statement provides diagnosis and management recommendations for systematic AL amyloidosis and AL cardiac amyloidosis under Taiwan's medical context.enAmyloidosisLight chain amyloidosisLight chain cardiac amyloidosis[SDGs]SDG17Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST).journal article10.1016/j.jfma.2025.05.00640368759